244 related articles for article (PubMed ID: 26475065)
1. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
3. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
[TBL] [Abstract][Full Text] [Related]
4. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
[TBL] [Abstract][Full Text] [Related]
6. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Li CY; Huang PM; Chu PY; Chen PM; Lin MW; Kuo SW; Lee JM
Biomed Res Int; 2016; 2016():6423297. PubMed ID: 27777949
[TBL] [Abstract][Full Text] [Related]
8. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
[TBL] [Abstract][Full Text] [Related]
9. Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer.
Abou-Jawde RM; Mekhail T; Adelstein DJ; Rybicki LA; Mazzone PJ; Caroll MA; Rice TW
Chest; 2005 Jul; 128(1):250-5. PubMed ID: 16002943
[TBL] [Abstract][Full Text] [Related]
10. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy.
Hsu FM; Lee YC; Lee JM; Hsu CH; Lin CC; Tsai YC; Wu JK; Cheng JC
Ann Surg Oncol; 2009 Jun; 16(6):1669-77. PubMed ID: 19267157
[TBL] [Abstract][Full Text] [Related]
11. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
Chung Y; Law S; Kwong DL; Luk JM
Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
[TBL] [Abstract][Full Text] [Related]
14. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
16. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
[TBL] [Abstract][Full Text] [Related]
17. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters.
Lee HK; Vaporciyan AA; Cox JD; Tucker SL; Putnam JB; Ajani JA; Liao Z; Swisher SG; Roth JA; Smythe WR; Walsh GL; Mohan R; Liu HH; Mooring D; Komaki R
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1317-22. PubMed ID: 14630268
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Yoon DH; Jang G; Kim JH; Kim YH; Kim JY; Kim HR; Jung HY; Lee GH; Song HY; Cho KJ; Ryu JS; Kim SB
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):489-96. PubMed ID: 25680595
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
World J Surg; 2014 Aug; 38(8):2046-51. PubMed ID: 24615604
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study.
Li QW; Qiu B; Wang B; Wang DL; Yin SH; Yang H; Liu JL; Fu JH; Liu MZ; Xie CM; Liu H
Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
